Table 3 Demographic and clinical characteristics of patients with IBD and inflammatory manifestations associated to SpA (n = 38)
Variables | n | % | |
|---|---|---|---|
BMI (Grade) | Normal | 8 | 21.1 |
Overweight | 18 | 47.4 | |
Grade 1 obesity | 6 | 15.8 | |
Grade 2 obesity | 2 | 5.3 | |
NA | 4 | 10.5 | |
BMI (Mean) | 26.73 ± 4.57 (19–37.5) | 34 | |
Gender | Female | 27 | 71.1 |
Age (years) | 45 ± 13 (17–70) | ||
Race | Caucasian | 25 | 65.8 |
Mixed ethnicity | 10 | 26.3 | |
Black | 3 | 7.9 | |
IBD | CD | 24 | 63.2 |
UC | 14 | 36.8 | |
IBD diagnosis time (years) | 10.32 ± 7.34 (1–22) | ||
HBI | 4.52 ± 2.21 (1–10) | ||
SCAII | 2 ± 1.12 (0–7) | ||
Current treatment | Topical | 4 | 10.5 |
Sulfasalazine or mesalazine | 8 | 21.1 | |
Azathioprine | 3 | 7.9 | |
Anti-TNF | 15 | 39.4 | |
Azathioprine and sulfasalazine | 6 | 15.8 | |
NA | 2 | 5.3 | |
At least one inflammatory musculoskeletal manifestation | 36 | 94.7 | |
Previous appointment with rheumatologist | 15 | 39.47 | |
Inflammatory low back pain | 19 | 50.0 | |
Past arthritis | 17 | 44.7 | |
Current arthritis | 3 | 7.9 | |
Past enthesitis | 10 | 26.3 | |
Current enthesitis | 2 | 5.3 | |
Past dactylitis | 4 | 10.5 | |
Past psoriasis | 2 | 5.3 | |
Past uveitis | 4 | 10.5 | |
SpA family history | 1 | 2.6 | |
Mechanical musculoskeletal pain | Peripheral pain | 7 | 18.4 |
Axial pain | 10 | 26.3 | |
Peripheral and axial pain | 4 | 10.5 | |
Diffuse pain | 1 | 2.6 | |
Total | 22 | 57.8 |